Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator during Weight Loss in Obese Women with and without Polycystic Ovary Syndrome.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27721826)

Published in Int J Endocrinol on September 18, 2016

Authors

Kai I Cheang1, Sakita N Sistrun2, Kelley S Morel3, John E Nestler4

Author Affiliations

1: Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, P.O. Box 980533, Richmond, VA 23298-0533, USA; Virginia Commonwealth University Institute for Women's Health, P.O. Box 980319, Richmond, VA 23298-0319, USA.
2: Bionutrition Service, Center for Clinical and Translational Research, Virginia Commonwealth University, P.O. Box 980155, Richmond, VA 23298-0155, USA.
3: Carilion Clinic Obstetrics & Gynecology, 102 Highland Ave, Suite 455, Roanoke, VA 24013, USA.
4: Virginia Commonwealth University Institute for Women's Health, P.O. Box 980319, Richmond, VA 23298-0319, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, P.O. Box 980111, Richmond, VA 23298-0111, USA.

Articles cited by this

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care (1999) 26.39

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA (2005) 9.61

Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem (1982) 5.98

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab (1998) 4.63

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab (2006) 4.56

Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet (2014) 2.11

Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab (1998) 2.10

Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care (2005) 1.96

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med (1999) 1.67

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 1.42

chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A (1993) 1.28

Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev (2011) 1.22

Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract (2004) 1.15

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril (2004) 1.15

Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. Diabetes (1997) 1.09

Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.02

Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care (2006) 1.01

Insulin mediators and the mechanism of insulin action. Adv Pharmacol (1993) 0.95

Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia (1997) 0.95

Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism (2008) 0.91

Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab Syndr Relat Disord (2010) 0.91

Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol (2010) 0.89

The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab (1988) 0.87

Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women. J Clin Endocrinol Metab (1999) 0.81

Does the presence of metabolic syndome influence weight loss in obese and overweight women? Metab Syndr Relat Disord (2010) 0.81

Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord (2016) 0.78